James Eason, MD
James Eason, MD
Professor of Surgery
Chief of Transplantation, UTHSC
Program Director, Methodist University Hospital James D. Eason Transplant Institute,
Memphis, TN
1982 - 1983 President, Mu Epsilon Delta (Pre-Medical Society)
1983 - 1987 U.S. Air Force Health Professions Scholarship Program
1986 - 1987 Internal Medicine and Surgery Student Feedback Committees
1986 Student Representative to Ad Hoc Committee Selecting Chairman of Obstetrics-Gynecology,
University of Tennessee
2002 Louisiana Hepatitis C Awareness Award presented by Senator John Breaux
2009 Memphis Business Journal Health Care Heroes
2009 Commercial Appeal – One of ‘Ten People who Impacted Memphis, TN over the last
Decade’
2011-2016 Memphis Magazine ‘Top Doctors”
2011 Cystic Fibrosis Breath of Life Honoree
2015 Tennessee Medical Association Outstanding Physician Award
- 1993 American Board of Surgery
- 2013 American Board of Surgery - Recertification
Astellas Pharma US, Inc.
A Phase2, Randomized Open-Label, Parallel Group, Multi-Center Study to assess the
Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients. – Principal
Investigator
Nycomed, Inc.
A Randomized, Open-Label, Parallel Group, Multi-Center Trial to Compare the Efficacy
and Safety of TachoSil® versus Standard Hemostatic Fleece Material for the Secondary
Treatment of Local Bleeding in Hepatic Resection Surgery. – Principal Investigator
Astellas Pharma, US, Inc.
A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label)
to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of
ASP8597 (Diannexin) in de novo Kidney Transplant Recipients. – Principal Investigator
Genentech, Inc.
A Phase 2/3, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate
The Safety And Efficacy of Efalizumab Compared with Cyclosporine, Both In Combination
With Mycophenolate Mofetil And Corticosteroids, As An Immunosuppressant Regimen in
De Novo Renal Transplantation. – Principal Investigator
Astellas Pharma, US, Inc.
A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose,
Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Study of ASKP1240 in de
novo Kidney Transplantation. – Principal Investigator
Astellas Pharma US, Inc.
A Phase2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the
Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients – Principal
Investigator
Grifols, Inc.
A prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and
Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During
Parenchymous Tissue Open Surgeries. – Principal Investigator
Baylor University Medical Center Annette C. and Harold C. Simmons Transplant Institute
A 36 Month Multi-Center, Open Label, Randomized, Comparator Study to Evaluate The
Efficacy And Carcinoma Exceeding Milan Criteria. – Sub-Investigator
Biotest Pharmaceuticals, Corporation, Inc.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the
Efficacy, Safety and Pharmacokinetics of Hepatitis C Immunoglubulin (HCIG) in Orthotopic
Liver Transplant Recipients. – Sub-Investigator
Massbiologics, Inc.
A Phase II Randomized, Double-blind, Placebo Controlled Study of the Clinical Effectiveness
of a Human Monoclonal Antibody against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1)
in Hepatitis C Infected Patients Undergoing Liver Transplantation. – Sub-Investigator